Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILD-TK01: Suicide Gene Therapy for DLI After HSCT
NCT01086735Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2010
- Primary completion
- Nov 2012
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HSV-Tk engineered donor lymphocytes in hematological malignancy, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Incidence of severe graft-versus-host disease at 12 months. Started Feb 2010; status: completed.
02
Drugs
HSV-Tk engineered donor lymphocytes
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT01086735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086735.